The global nucleic acid testing market size is set to reach USD 3.7 billion in 2023. Overall sales of nucleic acid testing are likely to surge at 6.8% CAGR, taking the forecasted market valuation to USD 7.2 billion by the end of 2033.
Increasing investment by government and private agencies in the development of novel biotechnological diagnostic techniques and high demand for technologically advanced diagnostic measures are projected to bolster the growth in the nucleic acid testing market.
Some approaches associated with nucleic acid testing are time-consuming, expensive, technically challenging, and not user-friendly, which are some of the factors contributing to the decline in BPS values.
The need for integrated systems with digitally improved data point displays with diagnostic patterns for identified pathogenesis arises from the inability of multiple devices to take into consideration the detection time for a disease and the sensitivity of the test at the same time.
Despite the fact that all nucleic acid testing devices provide quick sample-to-result diagnostics, their limitation of portability may render them unaffordable for most users in settings with limited resources. The present methods for nucleic acid testing have a number of limitations, thus impacting the demand within the nucleic acid testing market as a whole over the projected period.
Advances in technology are also driving the development of new nucleic acid analysis solutions. For example, CRISPR gene editing enables more accurate and efficient gene editing, while NGS is facilitating faster and more precise genomic analysis. These technologies are helping to improve the accuracy and speed of nucleic acid treatment and are making it possible to diagnose diseases and genetic disorders more quickly and effectively.
Another driver of growth is the growing demand for personalized medicine. Personalized medicine refers to the use of a patient's genetic information to customize medical treatment. nucleic acid treatment is a critical tool for personalized medicine, as it can provide insights into a patient's genetic makeup and help doctors develop tailored treatment plans.
This approach has been particularly successful in the field of oncology, where personalized treatment options are becoming increasingly common.
| Attributes | Details |
|---|---|
| Nucleic Acid Testing Market CAGR (2023 to 2033) | 6.8% |
| Nucleic Acid Testing Market Size (2023) | USD 3.7 billion |
| Nucleic Acid Testing Market Size (2033) | USD 7.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to recent research by Future Market Insights, the nucleic acid testing market is projected to expand at a rate of 6.8% during the forecast period from 2023 to 2033. The market outlook could be divided into short term, medium term and long term.
Short term (2023 to 2025): There has been an increase in the prevalence of infectious diseases. The COVID-19 pandemic, in particular, has highlighted the importance of rapid and accurate diagnostic testing. Nucleic acid treatment is a highly sensitive and specific method for detecting viral and bacterial infections, and is becoming an increasingly popular tool in the fight against infectious diseases.
Medium term (2025 to 2028): Automation and the development of point-of-care testing solutions are contributing to the growth of the nucleic acid analysis market. These innovations are making nucleic acid treatment more accessible and cost-effective, enabling healthcare providers to perform diagnostic testing in non-traditional settings, such as clinics and remote locations. This is particularly important in resource-constrained settings, where access to laboratory facilities may be limited.
Long term (2028 to 2033): There is a growing focus on using nucleic acid analysis for oncology applications, particularly for the detection of cancer biomarkers. This involves analyzing the genetic material in cancer cells to identify specific mutations or other markers that can be used to guide treatment decisions. This trend is driving the development of new cancer diagnostic assays and personalized treatment options, and has the potential to revolutionize the field of cancer treatment.
Ongoing technological advancements in the healthcare industry are expected to fuel the demand for nucleic acid tests. Various manufacturers operating in this market are developing in-house capabilities to come up with premium-quality nucleic acid test kits with short turn-around times for meeting different research requirements.
Besides this, the high demand for state-of-the-art methods in sample amplification, extraction, and preparation is set to spur the growth of this market. The need for nucleic acid test kits for the identification of RNA and DNA also is expected to augment the nucleic acid testing market growth.
Leading manufacturers are collaborating with various research institutes to co-develop novel nucleic acid test kits and bolster research activities in the field of molecular biology there is molecular nucleic acid testing. Many start-up companies are also anticipated to enter the market for nucleic acid testing to create new products and meet surging medical needs.
In December 2021, for instance, Roche, a multinational healthcare company based in Switzerland, introduced its latest infectious disease tests on a novel molecular laboratory instrument named cobas 5800 System for molecular nucleic acid testing in countries accepting the CE mark.
The new products include cobas omni-utility Channel kit, cobas HIV-1/HIV-2 Qualitative, cobas HCV, cobas HBV, and cobas HIV-1. HIV-1/HIV-2 Qualitative is an in vitro nucleic acid amplification test for the differentiation and detection of HIV-1 and HIV-2 in dried blood spots, plasma, and serum.
Such unique product launches by various key players have been projected to create prospects for the growth of the nucleic acid testing market in the near future. Additionally, the high demand for these kits from blood banks and blood transfusion centers is set to secure the entire blood transfusion. This is expected to emerge as escalated sales of nucleic acid testing.
Principal Consultant
| Countries | CAGR (2023 to 2033) |
|---|---|
| United States | 6.8% |
| United Kingdom | 6.7% |
| Japan | 6.3% |
| China | 7% |
| India | 10.6% |
The increasing cases of infectious diseases and the presence of well-established healthcare infrastructure are anticipated to spur the market in the United States. As per FMI, the North American nucleic acid testing market is likely to hold 34.2% of the market share in 2022.
Besides this, the surging prevalence of cancer in the United States is set to drive the demand for these diagnostic tests. The American Cancer Society mentioned that in the United States around 1.9 million new cancer cases are expected to be diagnosed in 2021.
| Attributes | Details |
|---|---|
| United States Market Size (2033) | USD 2 billion |
| United States Market Absolute Dollar Growth (USD million/billion) | USD 980.8 million |
Apart from that, the urgent need for better diagnostic tests for the detection of hepatitis B in this country is also set to fuel the growth. As per the Centers for Disease Control and Prevention (CDC), in 2018, approximately 3,322 new cases of hepatitis B were diagnosed in the United States.
Being the epicenter of the COVID-19 pandemic, China is projected to account for the largest market share. According to the analysis of FMI, the nucleic acid testing market is estimated to procure about 7.4% of the market share in 2022. The rising government initiatives to prevent the spread of the coronavirus were compelling manufacturers to produce innovative nucleic acid test kits in China.
| Attributes | Details |
|---|---|
| China Market Size (2033) | USD 659.1 million |
| China Market Absolute Dollar Growth (USD million/billion) | USD 324.2 million |
For instance, in December 2021, the capital of northeast China's Heilongjiang Province, Harbin, conducted the third nucleic acid testing in the main urban areas. This decision was taken after two positive COVID-19 cases were detected in the second nucleic acid testing.
Due to factors including growing knowledge of nucleic acid testing and a transfer in research institutes and contract research companies from developed western countries to emerging countries like India. Indian nucleic acid amplification testing market is predicted to have a greater CAGR than others.
| Attributes | Details |
|---|---|
| Japan Market Size (2033) | USD 525.6 million |
| Japan Market Absolute Dollar Growth (USD million/billion) | USD 241.3 million |
A huge population and a growing emphasis on healthcare systems are anticipated to cause Japan to grow at the quickest rate during the projected period. The Japanese nucleic acid amplification testing market prospects for nucleic acid testing can be improved by the high prevalence of new infectious diseases such as Japanese encephalitis, Hendra, and Nipah virus infections.
| Attributes | Details |
|---|---|
| United Kingdom Market Size (2033) | USD 267.5 million |
| United Kingdom Market Absolute Dollar Growth (USD million/billion) | USD 127.3 million |
Renowned manufacturers anticipate the United Kingdom to be one of the most flourishing countries in the market on the back of the increasing development of unique nucleic acid test kits. As per FMI, the Western Europe nucleic acid testing market is likely to hold about 17.0% of the market share in 2022.
The United Kingdom government is set to encourage the manufacturers of these tests to keep up with their production processes for meeting the high unmet needs. In November 2021, for instance, it published a Target Product Profile (TPP) which highlights updated intended use and changes to clinical sensitivity concerning these tests.
It aims to boost and support the development of innovative medical technologies to address the high demand in the United Kingdom
| Segment | Product Type |
|---|---|
| Top Sub-segment | Kits |
| CAGR (2017 to 2022) | 7.7% |
| CAGR (2023 to 2033) | 6.4% |
Based on product type, sales of nucleic acid testing kits are expected to surge at a rapid pace during the assessment period. In 2022, the segment is anticipated to showcase 89.5% in terms of the global nucleic acid testing market share, finds FMI.
Amongst the various types of nucleic acid test kits, the demand for Polymerase Chain Reaction (PCR) is projected to skyrocket in the upcoming years for the nucleic acid amplification testing market. These test kits have diverse applications in DNA mapping, cloning, typing, structural analysis, mutation analysis, and disease detection.
| Segment | Indication |
|---|---|
| Top Sub-segment | Infectious Diseases |
| CAGR (2017 to 2022) | 8.3% |
| CAGR (2023 to 2033) | 7.1% |
In terms of indication, infectious diseases are anticipated to surge at a fast pace in the near future in the nucleic acid amplification testing market because of the rising prevalence of tuberculosis and hepatitis B across the globe. As per the World Health Organization (WHO), in 2020, approximately 1.5 million people died because of tuberculosis worldwide.
The outbreak of the COVID-19 pandemic drove the demand for nucleic acid testing in various parts of the world. These are considered to be very efficient for epidemic control and patient management.
Based on end users, research institutes are expected to remain at the forefront in terms of nucleic acid testing market share over the forthcoming years. This dominance is attributable to the increasing number of research and development activities taking place in these institutes for the development of state-of-the-art nucleic acid testing.
In November 2021, for instance, Dutch researchers published a study in medRxiv, a preprint server, about the efficiency of isothermal nucleic acid amplification tests in the detection of SARS-CoV-2. They used pooled swab samples to compare the analytical sensitivity of different SARS-CoV-2 assays. The results showed that nucleic acid testing was more accurate than antigen assays in identifying contagious individuals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Nanopore
Maker of electronic devices based on nanopores for single-molecule analysis.
It creates nanopore-based devices that use DNA sequencing and exclusive electronics to find and recognize DNA bases. A microfluidic automated library preparation system is one of the tools and reagents for library preparation that are manufactured by this company. Additionally, it creates customized software for real-time analysis of data generated by sequencing equipment.
PacBio
Creator of software and instrumentation for single-molecule real-time sequencing.
It has created a Single-Molecule Real-Time sequencing platform using phospholinked nucleotides and Zero-Mode Waveguides, two of the company's exclusive technologies. Additionally, it creates analytical software for sequencing that helps with the polishing of results and sequence processing.
Key players operating in the nucleic acid testing market are focusing on expanding their production capacities to cater to the high demand worldwide. The emergence of new variants of the virus is set to compel them to cut down the costs of these tests while enhancing their efficacy.
Government agencies are likely to support the manufacturing companies by providing them with funds to produce test kits and supply them across the globe.
How can Manufacturers/Service Providers Scale their Businesses in the Nucleic Acid Testing Market?
Manufacturers and service providers in the nucleic acid testing market can take several steps to scale their businesses and increase their market share. Here are some key strategies:
Cepheid, a molecular diagnostics company, developed the Xpert Xpress SARS-CoV-2 test, a highly accurate and fast diagnostic test for COVID-19. The test can deliver results in as little as 30 minutes, making it a valuable tool for healthcare providers in the fight against the pandemic.
Qiagen, a provider of sample and assay technologies, expanded its business in China by opening a new production facility in Suzhou. The facility produces a range of diagnostic products, including nucleic acid treatment assays for infectious diseases.
Roche Diagnostics developed the cobas Liat System, a portable and easy-to-use nucleic acid treatment device that can deliver results in as little as 20 minutes. The system was developed in response to the need for rapid diagnostic testing in point-of-care settings, and has been well-received by healthcare providers.
Thermo Fisher Scientific, a provider of life science research tools, collaborated with the University of California San Francisco to develop a new NGS-based test for cancer patients. The test, which uses Thermo Fisher's Ion Torrent technology, can identify genetic mutations in cancer cells and help guide personalized treatment decisions.
The market is estimated to reach USD 7.2 billion by 2033.
The growth potential of the nucleic acid testing market is 6.8% CAGR through 2033.
The United States monopolizes the nucleic acid testing market.
Growing demand for effective testing alternatives for the management of disease outbreaks is expected to boost product sales.
Growing occurrence of cancerous, infectious, and genetic disorders is creating opportunities for manufacturers.
Explore Healthcare Insights
View Reports
Nucleic Acid Testing Market
